Active Surveillance for Prostate Cancer (2019)

Active surveillance is the recommended management for low-risk prostate cancer but is currently underutilized. This course includes five modules about active surveillance for prostate cancer, with a target audience of urologists, trainees and allied health professionals.

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers 

Learning Objectives

After completing this activity, participants will be able to:

  1. Summarize the guidelines on eligibility for Active Surveillance (AS).
  2. Explain a management plan for the frequency of PSA, DRE, and biopsy during AS.
  3. Evaluate the role and limitations of MRI during AS.
  4. Debate the utility of genomics/marker tests during AS.
  5. Explain when to stop AS, including reasons to convert to active treatment or to watchful waiting. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
07/30/2019
Course expires: 
07/30/2021
Rating: 
0

Education Council Disclosures

PDF iconEducation Council Disclosures

 

AUA Office of Education Staff have nothing to disclose. 

Course Director(s)

Stacy Loeb, MD

has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Stock) with Gilead;.
has a financial relationship (Stock) with Gilead;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Independent contractor) with Lumenis;.
has a financial relationship (Independent contractor) with Lumenis;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Lilly;.
Faculty(s)

Peter Carroll, MD, MPH

has a financial relationship (Other) with NIH;.
has a financial relationship (Other) with NIH;.
has a financial relationship (Independent contractor) with Insightec;.
has a financial relationship (Independent contractor) with Insightec;.
has a financial relationship (Independent contractor) with Nutcracker Therapeutics;.
has a financial relationship (Independent contractor) with Nutcracker Therapeutics;.
has a financial relationship (Other) with Department of Defense;.
has a financial relationship (Other) with Department of Defense;.

Matthew Cooperberg, MD

has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Other) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Other) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Steba;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Steba;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with GenomeDx;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with GenomeDx;.
has a financial relationship (Independent contractor) with Myriad Genetics;.
has a financial relationship (Independent contractor) with MDx Health;.
has a financial relationship (Independent contractor) with Myriad Genetics;.
has a financial relationship (Independent contractor) with MDx Health;.

Laurence Klotz, MD

has a financial relationship (Independent contractor) with TerSera;.
has a financial relationship (Independent contractor) with Sanofi Genzyme;.
has a financial relationship (Other) with Profound Medical;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Independent contractor) with MiRScientific;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Ferring Laboratories;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Profound Medical;.
has a financial relationship (Independent contractor) with Tolmar;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Ferring Laboratories;.
has a financial relationship (Independent contractor) with MiRScientific;.
has a financial relationship (Independent contractor) with Profound Medical;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Tolmar;.
has a financial relationship (Independent contractor) with TerSera;.
has a financial relationship (Independent contractor) with Sanofi Genzyme;.
has a financial relationship (Other) with Profound Medical;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Independent contractor) with Tolmar;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Independent contractor) with TerSera;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Profound Medical;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Independent contractor) with Ferring Laboratories;.
has a financial relationship (Independent contractor) with MiRScientific;.
has a financial relationship (Independent contractor) with Profound Medical;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Sanofi Genzyme;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Ferring Laboratories;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Profound Medical;.
has a financial relationship (Independent contractor) with Tolmar;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Sanofi Genzyme;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Independent contractor) with TerSera;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Profound Medical;.
has a financial relationship (Independent contractor) with MiRScientific;.
has a financial relationship (Other) with Janssen;.

Daniel Lin, MD

has a financial relationship (Other) with MagForce USA;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Other) with NIH/NCI;.
has a financial relationship (Independent contractor) with Clovis Oncology;.
has a financial relationship (Other) with Department of Defense;.
has a financial relationship (Other) with Genomic Health, Inc.;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Other) with NIH/NCI;.
has a financial relationship (Other) with MagForce USA;.
has a financial relationship (Other) with Genomic Health, Inc.;.
has a financial relationship (Independent contractor) with Clovis Oncology;.
has a financial relationship (Other) with Department of Defense;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the online modules and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.00 hours

Release Date: July, 2019
Expiration Date: July, 2021

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.